Trial Profile
A Phase II Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2017 New trial record